Veterinary Medicines

Vanguard DA2PI-CPV Lyophilisat et solvant pour suspension injectable pour chiens

Authorised
  • Canine distemper virus, strain N-CDV, Live
  • Canine parvovirus, strain NL-35-D, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain NL-CPI-5, Live
Download as PDF

Product identification

Medicine name:
Vanguard DA2PI-CPV Lyophilisat et solvant pour suspension injectable pour chiens
Vanguard DA2PI-CPV Lyophilisat und Lösungsmittel zur Herstellung einer Injektionssuspension
Active substance:
  • Canine distemper virus, strain N-CDV, Live
  • Canine parvovirus, strain NL-35-D, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain NL-CPI-5, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine distemper virus, strain N-CDV, Live
    3.00
    log10 cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Canine parvovirus, strain NL-35-D, Live
    7.00
    log10 cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Canine adenovirus 2, strain Manhattan, Live
    3.20
    log10 cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Canine parainfluenza virus, strain NL-CPI-5, Live
    6.00
    log10 cell culture infective dose 50
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Luxembourg
Available in:
  • Luxembourg
Package description:
  • Vanguard DA2PI-CPV 1 dose Vial Lyophilisate and solvent for suspension for injection
  • Vanguard DA2PI-CPV 10 1 dose Vial Lyophilisate and solvent for suspension for injection
  • Vanguard DA2PI-CPV 100 1 dose Vial Lyophilisate and solvent for suspension for injection
  • Vanguard DA2PI-CPV 25 1 dose Vial Lyophilisate and solvent for suspension for injection

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Belgium
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Ministere De La Sante Division De La Pharmacie Et Des Medicaments
Authorisation number:
  • V 087/93/11/0351
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 16/01/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."